Clinical assessment of low molecular weight heparin effects in peripheral vascular disease.
This study was carried out, using the double-blind method vs placebo, on 36 patients suffering from stage II peripheral vascular disease (PVD) according to Leriche, to check the clinical and hemorrheologic effects of the administration of a new low molecular weight heparin (LMWH). After a one-month washout period, the patients were randomly assigned either to the group treated with the LMWH (15,000 aXaU/day sc) or to the group treated with indistinguishable placebo. At the start of the study and after three and six months of treatment, clinical, instrumental, and laboratory tests were performed to assess local and systemic efficacy and tolerance. The LMWH under study caused a statistically significant increase in claudication time, with a parallel increase in the absolute claudication distance and in the interval free of pain. The drug also led to a significant increase in activated partial thromboplastin time, the values of which, however, remained within the normal limits, and to a marked reduction in blood viscosity. No significant variation was observed in the tolerability parameters in the two treatment groups, and no local or systemic adverse reactions occurred.
Calabrò
A
A
Institute of Internal Medicine, Chair of I Medical Pathology, University of Padua, Italy.
Piarulli
F
F
Milan
D
D
Rossi
A
A
Coscetti
G
G
Crepaldi
G
G
D000368:Aged; D001157:Arterial Occlusive Diseases / Q000097:blood / Q000188:drug therapy*; D001780:Blood Coagulation Tests; D001809:Blood Viscosity / Q000187:drug effects; D004311:Double-Blind Method; D017079:Exercise Tolerance; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D016138:Walking
D006495:Heparin, Low-Molecular-Weight